AbbVie ROA 2010-2022 | ABBV

Current and historical return on assets (ROA) values for AbbVie (ABBV) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
AbbVie ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $12.64B $143.19B 8.69%
2022-03-31 $12.48B $143.21B 8.51%
2021-12-31 $11.54B $146.53B 7.77%
2021-09-30 $7.53B $148.86B 5.04%
2021-06-30 $6.66B $147.97B 4.45%
2021-03-31 $5.16B $150.50B 3.44%
2020-12-31 $4.62B $150.57B 3.41%
2020-09-30 $7.38B $149.62B 6.16%
2020-06-30 $6.96B $149.53B 7.15%
2020-03-31 $8.44B $91.20B 11.37%
2019-12-31 $7.88B $89.12B 12.01%
2019-09-30 $3.26B $59.44B 5.60%
2019-06-30 $4.12B $57.14B 6.88%
2019-03-31 $5.36B $56.77B 8.79%
2018-12-31 $5.69B $59.35B 8.87%
2018-09-30 $7.57B $66.16B 11.29%
2018-06-30 $6.45B $61.64B 9.53%
2018-03-31 $6.38B $69.34B 9.25%
2017-12-31 $5.31B $70.79B 7.80%
2017-09-30 $6.65B $68.84B 9.94%
2017-06-30 $6.62B $66.99B 9.97%
2017-03-31 $6.31B $65.66B 9.50%
2016-12-31 $5.95B $66.10B 9.39%
2016-09-30 $6.08B $66.63B 10.11%
2016-06-30 $5.72B $67.21B 10.00%
2016-03-31 $5.48B $53.72B 10.17%
2015-12-31 $5.14B $53.05B 10.92%
2015-09-30 $2.82B $54.83B 6.92%
2015-06-30 $2.08B $53.86B 6.11%
2015-03-31 $1.82B $26.70B 6.50%
2014-12-31 $1.77B $27.51B 6.24%
2014-09-30 $3.71B $28.45B 12.87%
2014-06-30 $4.17B $29.05B 14.49%
2014-03-31 $4.14B $28.66B 14.52%
2013-12-31 $4.13B $29.20B 14.67%
2013-09-30 $4.54B $28.25B 16.46%
2013-06-30 $5.16B $27.91B 19.70%
2013-03-31 $5.36B $27.17B 22.66%
2012-12-31 $5.28B $27.01B 24.42%
2012-09-30 $4.89B $22.73B 24.79%
2012-06-30 $3.32B $17.71B 23.63%
2012-03-31 $3.59B $18.96B 37.35%
2011-12-31 $3.43B $19.52B 70.34%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $249.673B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17